[Federal Register Volume 84, Number 67 (Monday, April 8, 2019)]
[Notices]
[Pages 13927-13928]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-06815]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-19-0009; Docket No. CDC-2019-0014]


Proposed Data Collection Submitted for Public Comment and 
Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice with comment period.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part 
of its continuing effort to reduce public burden and maximize the 
utility of government information, invites the general public and other 
Federal agencies the opportunity to comment on a proposed and/or 
continuing information collection, as required by the Paperwork 
Reduction Act of 1995. This notice invites comment on a proposed 
information collection project titled ``National Disease Surveillance 
Program--I. Case Reports'' to collect disease-specific surveillance 
reports of four rare, uncommon, or infrequent diseases.

DATES: CDC must receive written comments on or before June 7, 2019.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2019-
0014 by any of the following methods:
     Federal eRulemaking Portal: Regulations.gov. Follow the 
instructions for submitting comments.
     Mail: Jeffrey M. Zirger, Information Collection Review 
Office, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE, MS-D74, Atlanta, Georgia 30329.
    Instructions: All submissions received must include the agency name 
and Docket Number. CDC will post, without change, all relevant comments 
to Regulations.gov.

    Please note:  Submit all comments through the Federal 
eRulemaking portal (regulations.gov) or by U.S. mail to the address 
listed above.


FOR FURTHER INFORMATION: To request more information on the proposed 
project or to obtain a copy of the information collection plan and 
instruments, contact Jeffrey M. Zirger, Information Collection Review 
Office, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from 
the Office of Management and Budget (OMB) for each collection of 
information they conduct or sponsor. In addition, the PRA also requires 
Federal agencies to provide a 60-day notice in the Federal Register 
concerning each proposed collection of information, including each new 
proposed collection, each proposed extension of existing collection of 
information, and each reinstatement of previously approved information 
collection before submitting the collection to the OMB for approval. To 
comply with this requirement, we are publishing this notice of a 
proposed data collection as described below.
    The OMB is particularly interested in comments that will help:
    1. Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    2. Evaluate the accuracy of the agency's estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    3. Enhance the quality, utility, and clarity of the information to 
be collected; and
    4. Minimize the burden of the collection of information on those 
who are to respond, including through the use of appropriate automated, 
electronic, mechanical, or other technological collection techniques or 
other forms of information technology, e.g., permitting electronic 
submissions of responses.
    5. Assess information collection costs.

Proposed Project

    National Disease Surveillance Program--I. Case Reports--Revision--
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), 
Centers for Disease Control and Prevention (CDC).

Background and Brief Description

    Surveillance of the incidence and distribution of disease has been 
an important function of the US Public Health Service (PHS) since an 
1878 Act of Congress authorized the PHS to collect morbidity reports. 
After the Malaria Control in War Areas Program had fulfilled its 
original 1942 objective of reducing malaria transmission, its basic 
tenets were carried forward and broadened by the formation of the 
Communicable Disease Center (CDC) in 1946. CDC was conceived of as a 
well-equipped, broadly staffed agency used to translate facts about 
analysis of morbidity and mortality statistics on communicable diseases 
and through field investigations.
    It was soon recognized that control measures (such as the DDT 
spraying for malaria) did not alleviate the threat of disease 
reintroduction. In 1950, the Malaria Surveillance Program began and in 
1952, the National Surveillance Program started. Both programs were 
based on the premise that diseases cannot be diagnosed, prevented, or 
controlled until existing knowledge is expanded and new ideas developed 
and implemented. The original scope of the National Surveillance 
Program included the study of malaria, murine typhus, smallpox, 
psittacosis, diphtheria, leprosy, and sylvatic plague. Over the years, 
the mandate of CDC has broadened in preventive health activities and 
the surveillance systems maintained have expanded. This program is 
authorized under the Public Health Service Act, Section 301 and 306 (42 
U.S.C. 241 and 242K).
    This ICR covers surveillance activities for these four, rare 
diseases:

1. Creutzfeldt-Jakob Disease (CJD)
2. Reye Syndrome
3. Kawasaki syndrome
4. Acute Flaccid Myelitis

    Changes are being requested only to the Kawasaki Syndrome form. The 
CDC KD form has been used as part of a passive national surveillance 
system to collect additional case information, including data on 
cardiac complications and treatment. In recent years, new treatments 
and/or treatment combinations have been implemented at some 
institutions; this information is not collected on the current form. 
Also, more specific information regarding the results of coronary 
artery testing would be beneficial for assessing disease severity and 
treatment effectiveness. To incorporate these additions to the form 
without increasing the estimated burden, some current questions on the 
form, specifically those collecting information on the presence or 
absence of certain complications, will be removed. The form will be 
targeted to sentinel KD research centers across the US, reducing the 
number of respondents compared to previous years.
    Annual burden is estimated to decrease by 53 hours since the last 
approval (June, 2019). There is no cost

[[Page 13928]]

to respondents other than the time to participate.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                     Number of    Average burden
      Type of respondents           Form name        Number of     responses per   per response    Total burden
                                                    respondents     respondent      (in hours)      (in hours)
----------------------------------------------------------------------------------------------------------------
Epidemiologists...............  CJD.............              10               2           20/60               7
                                Kawasaki                      25              10           15/60              63
                                 Syndrome.
                                Reye Syndrome...              50               1           20/60              17
                                Acute Flaccid                100               1           30/60              50
                                 Myelitis.
                                                 ---------------------------------------------------------------
    Total.....................  ................  ..............  ..............  ..............             137
----------------------------------------------------------------------------------------------------------------


Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific 
Integrity, Office of Science, Centers for Disease Control and 
Prevention.
[FR Doc. 2019-06815 Filed 4-5-19; 8:45 am]
 BILLING CODE 4163-18-P